Cytokinetics Prices Upsized $700M Public Offering at $71.00/Share to Fund MYQORZO Launch and Pipeline

summarizeSummary

Cytokinetics priced an upsized public offering of common stock at $71.00 per share, raising up to $760.2 million in net proceeds to fund the commercial launch of MYQORZO and advance its pipeline, capitalizing on recent positive clinical trial results.

check_boxKey Events

• Upsized Public Offering Priced

  Cytokinetics priced 9,859,155 shares of common stock at $71.00 per share, with underwriters having an option to purchase an additional 1,478,873 shares.

• Significant Capital Raise

  The offering is expected to generate net proceeds of approximately $661.0 million, potentially increasing to $760.2 million if the underwriters' option is fully exercised.

• Strategic Use of Proceeds

  Net proceeds will be used for the commercial launch of MYQORZO, advancing the company's pipeline, and general corporate purposes, including working capital.

• Potential Share Dilution

  The offering will result in an immediate dilution of $72.23 per share for new investors, and increases the total outstanding shares to 134,096,978 (or 135,575,851 with full option exercise).

auto_awesomeAnalysis

Cytokinetics has finalized the terms of its public offering, pricing 9,859,155 shares of common stock at $71.00 per share. This offering, which includes an option for underwriters to purchase an additional 1,478,873 shares, is expected to generate net proceeds of approximately $661.0 million, or $760.2 million if the option is fully exercised. This substantial capital raise follows the highly positive topline results from the Phase 3 ACACIA-HCM clinical trial for aficamten announced on May 5, 2026, and the offering price of $71.00 represents a premium to the stock's closing price of $66.05 on May 4, 2026, prior to the news. The proceeds are earmarked for the commercial launch of MYQORZO, advancing the company's pipeline, and general corporate purposes, including working capital. While the offering is dilutive to existing shareholders, it significantly strengthens the company's financial position to support its transition to a commercial-stage biopharmaceutical company and capitalize on recent clinical successes.